Drug Trial Radar · NCT03509831
[KJ-INT-002] BE Study
Last checked: Nov 20, 2026Latest source record: Apr 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
37
Actual
Start
Nov 2, 2017
Primary completion
Jan 24, 2018
Study completion Apr 2018
Sponsor
- Lead sponsor
- Kukje PharmaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral Administration to Healthy Adult Male Subjects
Conditions
- Gastritis
Interventions
INT-2150Drug
1. Period: INT-2150 2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg
Irsogladine maleate 2 mg+Nizatidine 150 mgDrug
1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg 2. Period: INT-2150
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCtTime frame: One day
- CmaxTime frame: One day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kukje Pharm
Seongnam-si, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.